Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

NCT06528769 is registered in ClinicalTrials.gov with Gabriel Tinoco as lead sponsor.

NCT NCT06528769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06528769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Lead sponsor
Gabriel Tinoco
Phase
Phase 2
Overall status
Recruiting
Start date
September 10, 2025
Completion date
December 31, 2027
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma, sarcoma